Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUDI: Trastuzumab Deruxtecan and Durvalumab in Stage III Inflammatory Breast Cancer
NCT05795101Phase 2Recruiting
- Sponsor
- Filipa Lynce
- Start
- May 2023
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, durvalumab in inflammatory breast cancer (IBC), sponsored by Filipa Lynce. Started May 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecandurvalumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT05795101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795101.